Beyond The Numbers: 4 Analysts Discuss Certara Stock

In the preceding three months, 4 analysts have released ratings for Certara (NASDAQ:CERT), presenting a wide array of perspectives from bullish to bearish.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

	Bullish	Somewhat Bullish	Indifferent	Somewhat Bearish	Bearish
Total Ratings	1	0	3	0	0
Last 30D	0	0	1	0	0
1M Ago	1	0	0	0	0
2M Ago	0	0	0	0	0
3M Ago	0	0	2	0	0

Insights from analysts' 12-month price targets are revealed, presenting an average target of $16.0, a high estimate of $18.00, and a low estimate of $14.00. Observing a downward trend, the current average is 9.86% lower than the prior average price target of $17.75.

Decoding Analyst Ratings: A Detailed Look

The standing of Certara among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst	Analyst Firm	Action Taken	Rating	Current Price Target	Prior Price Target
Luke Sergott	Barclays	Lowers	Equal-Weight	$14.00	$16.00
Dan Leonard	UBS	Maintains	Buy	$16.00	$16.00
Dan Leonard	UBS	Lowers	Neutral	$16.00	$20.00
Joe Vruwink	Baird	Lowers	Neutral	$18.00	$19.00

Key Insights:

• Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Certara. This offers insight into analysts' perspectives on the current state of the company.
• Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Certara compared to the broader market.
• Price Targets: Gaining insights, analysts provide estimates for the future value of Certara's stock. This comparison reveals trends in analysts' expectations over time.

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Certara's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on Certara analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Get to Know Certara Better

Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.

Financial Insights: Certara

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

Revenue Growth: Certara displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 3.17%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Certara's net margin excels beyond industry benchmarks, reaching -13.48%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Certara's ROE stands out, surpassing industry averages. With an impressive ROE of -1.2%, the company demonstrates effective use of equity capital and strong financial performance.

Return on Assets (ROA): Certara's ROA stands out, surpassing industry averages. With an impressive ROA of -0.82%, the company demonstrates effective utilization of assets and strong financial performance.

Debt Management: Certara's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.3.

The Basics of Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.